Here are the latest G-BA decisions from the G-BA meeting held on 2 April 2026 on the early benefit assessments of Ekterly, Ogsiveo, and on the RWE of Roctavian.
A database of all previous G-BA resolutions is available in my store.
- Ekterly (sebetralstat): Hereditary angioedema, acute treatment, ≥ 12 years – Orphan drug, Hint of not-quantifiable additional benefit
- Ogsiveo (nirogacestat): Desmoid tumor, advanced – Orphan drug, Hint of minor additional benefit
- Roctavian (valoctocogen roxaparvovec): Severe hemophilia A) – Termination of RWE collection and prescribing restriction, because manufacturer did not submit RWE study protocol and interim results